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1. INTRODUCTION
The COVID-19 pandemic is acutely threatening access to essential health 
services, including abortion.[1] Across all fields of medicine, changes in 
practice models are occurring rapidly. For patients seeking abortion, urgent 
modifications of current protocols are needed to ensure that patients can 
continue to obtain this time-sensitive treatment while limiting transmission 
of infection by maintaining distance between and among patients and 
providers. Remote delivery of care, which has recently been endorsed by 
local, state, and federal authorities as a key epidemic control measure,[2] 
will be indispensable to accommodate patients and staff who are navigating 
quarantines, stay-at-home directives, lack of transportation, new family or 
work obligations, or other unavoidable circumstances that impede their 
ability to go in in person to a health facility.
Fortunately, medication abortion (MA) using mifepristone and misoprostol 
can address many of these challenges. At present, MA typically entails a visit
to a clinician or facility that provides abortion where an ultrasound or pelvic 
examination and often blood tests are performed to evaluate eligibility 
before pills are dispensed. Many abortion providers require a follow-up 
ultrasound or blood test after treatment to confirm abortion completion. 
However, research and experience have demonstrated that these tests, 
which inherently involve physical contact between patient and health care 
worker, are usually unnecessary for safe and effective MA.[3-7] Indeed, over 
the past 15 years, international organizations have provided mifepristone 
and misoprostol by mail to tens of thousands of patients screened only by 
history.[8-11] A prospective study conducted in 2015-2016 in the United 
States, Mexico, and Moldova provided 406 MAs without screening ultrasound 
or pelvic examination.[12] No serious adverse events were reported that 
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To assist abortion providers with the current crisis, we present a sample 
protocol (Figure 1) for providing a "no-test" MA that includes 
recommendations for patient selection, Rh status evaluation and 
management, the treatment regimen, and follow-up. Although FDA-imposed 
restrictions on mifepristone dispensing may require patients to present to 
the abortion provider or facility to obtain the drug,[13] this protocol would 
enable every other part of the MA process to be implemented without any in-
person encounter. The protocol is intended to serve as a guidance; abortion 
providers should use clinical judgment when adapting it for their practice 
settings and patient populations. Below we summarize the data that we 
considered in developing this protocol and our rationales for and comments 
on selected provisions. 
2. PATIENT SELECTION
The three key goals of clinical evaluation before MA are (1) to confirm that 
the gestational age (GA) is within accepted limits for effective and safe 
outpatient treatment, (2) to exclude ectopic pregnancy, and (3) to establish 
that the patient has no other contraindications to MA. 
The sample no-test MA protocol specifies an upper GA limit of 77 days as 
estimated from the first day of the last menstrual period (LMP). The LMP-
based GA should be ≤77 days on the day of mifepristone ingestion, which 
may be later than the day the drug is dispensed if the patient plans to take 
the pills home for later use or if the medication is mailed or dispensed to a 
patient intermediary. The patient should be certain within one week of the 
LMP onset date. 
We chose a 77-day limit because recent data have indicated that outpatient 
MA is safe and effective through that GA[14,15] and because this limit is 
consistent with current guidelines of the National Abortion Federation[16] 
and Planned Parenthood Federation of America (personal communication, 
Gillian Dean, MD, MPH, Planned Parenthood Federation of America). We note,
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and Gynecologists (ACOG) and the Society for Family Planning[17] as well as 
the mifepristone label approved by the US Food and Drug Administration in 
2016 specify a 70-day limit. In response to the pandemic, ACOG has recently
issued a statement acknowledging that LMP-based gestational dating without
ultrasound is acceptable, although no specific GA limit was specified.[18]
Regardless of the precise GA limit selected, use of the no-test approach will 
inevitably result in treatment of some fraction of patients whose true GAs 
exceed 77 days. Data from studies that compared LMP-based GA estimates 
to ultrasound-based estimates suggest that this fraction tends to be higher in
patient populations that include more patients with advanced GA[19,20] and 
that it may be reduced by decreasing the LMP-based GA cutoff.[19] 
Reassuringly, the largest study, which was conducted in the United States in 
2005-2007,[21] found that only 31 (1%) of 3,012 MA patients who were 
certain that their LMPs had started ≤77 days prior had GAs >77 days by 
ultrasound examination. Furthermore, international studies that included 
nearly two thousand patients treated with mifepristone and one or more 
misoprostol doses at 13-24 weeks of gestation reported efficacy and safety 
similar to that expected in earlier gestation: >93% of patients aborted 
without further intervention, 0.7-4% required transfusion, and no patient 
required hysterectomy or died.[22] Therefore, we expect that serious 
adverse health consequences of GA underestimation based on LMP will be 
rare. Nevertheless, clinicians using the no-test approach to MA should have a
plan for managing or referring patients who may need a second trimester 
procedure to complete the abortion.
When assessing GA, providers may incorporate other historical information 
reported by the patient that, for simplicity, we do not mention in the sample 
protocol but that may indicate that the GA is greater than the proposed limit.
For example, a patient who reports a positive pregnancy test >7 weeks 
before presentation is unlikely to have a GA of ≤77 days. The sample 
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recent use of hormonal contraceptives. Although these conditions may signal
ovulatory dysfunction, we expect that they would more likely lead to 
overestimation of GA than to underestimation, which is the primary concern 
for MA eligibility, and excluding patients with these conditions may therefore 
unnecessarily limit access by eligible patients.
MA with mifepristone and misoprostol is contraindicated in patients with 
ectopic pregnancy not because the drugs are dangerous for such patients 
but because the regimen is not a proven treatment for this condition. The 
sample no-test protocol excludes patients with significant symptoms of or 
risk factors for ectopic pregnancy; recent vaginal bleeding or pelvic pain, 
prior permanent contraception, prior ectopic pregnancy, or intrauterine 
device in place at conception.[23,24] We do not exclude patients who report 
prior pelvic inflammatory disease because unconfirmed diagnoses of this 
condition are associated with only a mildly increased risk.[24] We recognize 
that the listed criteria will not identify every patient with ectopic pregnancy; 
an estimated half of all patients with this condition have no risk factors.[25] 
However, published and emerging data suggest that the incidence of ectopic
pregnancy among patients seeking MA is very low, <1%.[26,27] Moreover, 
substantial data[28-32] and current clinical MA guidelines[16,33] support 
treatment of patients in whom ectopic pregnancy has not been definitively 
excluded because the condition can be detected and managed afterwards. 
Thus, this aspect of the protocol is consistent with the standard of care.
The medical contraindications in the sample protocol are those listed in the 
FDA-approved mifepristone label. Patient history is sufficient for assessing 
these conditions. 
3. RH TYPING AND OTHER PRE-TREATMENT LABORATORY TESTING
Recent research has suggested that the risk of Rh sensitization after early 
abortion is negligible.[34-36] Consequently, the National Abortion Federation
has concluded that forgoing Rh typing and administration of anti-D 
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abortion before 56 days of gestation and may be considered for all patients 
having MA at less than 70 days.[16,37] The sample protocol is consistent 
with this conclusion. In addition, it specifies that testing is unnecessary for 
patients who can report a Rh-positive blood type or who are certain that they
want no future children after the planned abortion. Any patient may opt out 
of Rh typing; the recent statement from ACOG notes that Rh testing and RhD
immunoglobulin administration should not be a barrier to the provision of 
medication abortion.[18]
Hemoglobin/hematocrit and other laboratory tests are not routinely needed 
before first-trimester abortion but may be performed as indicated by medical
history and patient symptoms.[16]
4. TREATMENT REGIMEN 
The sample protocol specifies that patients should receive a standard 
regimen of mifepristone 200 mg orally and misoprostol 800 mcg vaginally or 
buccally.[16] In addition, each patient should be provided with an extra dose 
of misoprostol 800 mcg. Those with estimated GA >63 days should be 
instructed to take this second misoprostol dose 4 hours after the first to 
improve effectiveness.[16,38] Patients with estimated GA <63 days may be 
instructed to take the second dose if no bleeding occurs within the first 24 
hours after the first dose or to retain it for use if recommended by the 
provider. Alternatively, all patients may be told to take two misoprostol 
doses 4 hours apart. Although this specific regimen has not been studied, 
trials of repeated doses of misoprostol in the first and second trimester 
suggest that it will be safe.[39-43] 
5. SCHEDULED FOLLOW-UP
The primary goals of follow-up are to confirm absence of continuing 
pregnancy, to detect ectopic pregnancies not diagnosed before treatment, 
and to identify complications that need evaluation and treatment. To 
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high sensitivity urine pregnancy tests (HSPTs) that the patient performs at 
home. This strategy has been validated in several studies,[44,45] is 
consistent with current MA guidelines for follow-up of patients who have 
documented intrauterine pregnancies,[16,17] and is increasingly used by MA
providers. 
The sample instruction sheet (Figure 2), which includes a list of symptoms 
that may need in-person evaluation, is derived from studies of symptoms 
used to assess outcomes in MA patients with intrauterine pregnancies 
documented by ultrasound[44-47] and from experience in managing patients
with ectopic pregnancies. The instruction sheet directs patients to contact 
the abortion provider if specified symptoms occur or the HSPT result is 
positive. Research has shown that patients can safely use these tools on 
their own to recognize when follow-up is needed,[48,49] and indeed patient-
controlled follow-up is widely used for MA follow-up by provider organizations
in multiple European countries.[50-52] However, the sample no-test protocol 
recommends a planned follow-up contact with the provider one week after 
dispensing the abortifacient medications to confirm absence of symptoms of 
ongoing or undiagnosed ectopic pregnancy or other potential complications. 
This contact may be conducted by videoconference, telephone, patient 
portal, email, text, or other telehealth modalities.[53,54]
MA failures are often detectable based on symptoms alone.[6,44,47-49] 
Nevertheless, the sample no-test protocol recommends a HSPT 4 weeks after
misoprostol use to confirm pregnancy termination. Available data indicate 
that 5-25% of HSPTs performed about a month after MA treatment produce 
positive results, nearly all of which are "false positives" in patients who no 
longer have viable pregnancies.[44,45] Therefore, the sample protocol 
recommends that two HSPTs be provided initially to each patient. The 
patient should be instructed to call the provider if the result of the initial 4-
week test is positive. If the patient is asymptomatic, a repeat test one week 
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pregnancy or the second HSPT result is positive, further evaluation is 
indicated. The specific procedures for this evaluation should address the 
patient's individual clinical situation and may include ultrasound, serial 
serum HCG levels, additional urine pregnancy testing, or aspiration and 
tissue examination. 
Patients receiving a no-test MA may remain at risk for having ectopic 
pregnancy until a negative HSPT result is obtained. Therefore, vigilant 
attention on the part of both provider and patients to symptoms such as 
increased pelvic or abdominal pain, continued vaginal bleeding, or dizziness 
is imperative. 
6. COUNSELING
Patients requesting a no-test MA should receive standard pre-abortion 
counseling about pregnancy options, the risks and benefits of MA, expected 
results, side effects, and warning signs. In addition, each patient should be 
explicitly informed that LMP-based dating may underestimate GA, in which 
case efficacy may be lower than expected, bleeding and cramping may be 
heavier, and, rarely, fetal tissue may be visible. Moreover, patients should 
understand that without ultrasound, ectopic pregnancy will not be 
definitively excluded before treatment. To increase the chance of abortion 
success and reduce the time to diagnosis of ectopic pregnancy or MA 
complications, patients should be advised to diligently follow all instructions 
provided. However, patients should also be advised that serious adverse 
events of no-test abortion are expected to be rare and that side effects of MA
can often be managed remotely. To avoid unnecessary infectious exposure 
during a pandemic as well as excess cost and inconvenience, patients should
contact the abortion provider before seeking in-person care. 
7. CONCLUSION
Although the COVID-19 crisis prompted the development of this sample 
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serious impediments to abortion access in the United States. Omitting 
unnecessary use of ultrasound, examination, and laboratory tests before MA 
can reduce barriers to this essential service by decreasing cost and 
enhancing convenience and comfort. The no-test approach can enable 
provision of abortion in new venues and by new categories of providers, and 
it can facilitate new service delivery models, such as synchronous or 
asynchronous telehealth, stationary or mobile "mini-clinics", pill pick-up 
arrangements, or dispensing via lockboxes or, potentially, by mail.[7,54] If 
the no-test strategy results in earlier treatment, it may increase MA success 
rates.[14,43,55] Details of the no-test MA protocol will certainly need to be 
revised as new evidence emerges, but we anticipate that this approach to 
providing the service will continue to be beneficial for both patients and 
abortion providers even after the current epidemic resolves. 
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Figure 1. Sample Protocol for No-Test Medication Abortion
PURPOSE 
To enable safe and effective provision of medication abortion without a mandatory pre-
treatment ultrasound, pelvic examination or laboratory tests when medically appropriate, 
given that these tests may be significant barriers to access and, in the setting of a pandemic, 
may increase transmission of infection to patients and health care workers.
CRITERIA
 Pregnancy confirmed by patient report of urine or serum test or prior ultrasound
 Last menstrual period started ≤77 days before anticipated date of mifepristone ingestion
 Certain of last menstrual period onset date  1 week 
 None of the following symptoms or risk factors for ectopic pregnancy:
o Vaginal bleeding or spotting within the past week
o Unilateral pelvic pain or significant bilateral pelvic pain within the past week
o Prior ectopic pregnancy 
o Prior permanent contraception or other tubal surgery
o IUD in uterus at conception or currently
 None of the following contraindications to medication abortion, assessed by history:
o Hemorrhagic disorder or concurrent anticoagulant therapy
o Chronic adrenal failure
o Concurrent long-term systemic corticosteroid therapy
o Inherited porphyria
o Allergy to mifepristone, misoprostol, or other prostaglandin
 No strong preference for pre-treatment ultrasound, pelvic examination or laboratory tests
RH TYPING AND ADMINISTRATION OF ANTI-D IMMUNOGLOBULIN
 Not needed if the gestational age on the anticipated mifepristone ingestion date will be 
<70 days or if the patient reports positive Rh type, wants no future children, or declines 
anti-D immunoglobulin.
 Should be considered for women not meeting above criteria
TREATMENT 
Provide the following:
 Mifepristone 200 mg orally
 Misoprostol 800 mcg x 2
 Analgesics, antiemetics per health facility protocol
 Patient instruction sheet and health facility emergency contact information
 Two high sensitivity pregnancy tests (HSPTs)
The patient should take mifepristone 200 mg orally followed by misoprostol 800 mcg buccally 
or vaginally 24-48 hours later. Patients with estimated GA >63 days should take a second dose
of misoprostol 800 mcg 4 hours after the first. Patients with estimated GA ≤63 days should 
take the second dose if no bleeding occurs within the first 24 hours after the first misoprostol 
dose or if instructed to take it by a clinician. Review the instruction sheet with the patient.
FOLLOW-UP
1. Plan a follow-up contact with the patient one week after dispensing treatment. 
2. If the patient reports indicators of continuing or ectopic pregnancy (e.g., any of the 
symptoms on the instruction sheet), evaluate with ultrasound or serum HCGs.
3. Otherwise, instruct the patient to perform the first HSPT 4 weeks after taking misoprostol 
(not earlier) and to contact the abortion provider if the result is positive.
4. If the patient has indicators of continuing or ectopic pregnancy, evaluate with ultrasound or
serum HCGs
5. If the first HSPT result is positive but the patient has no such indicators, instruct the patient
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6. If second HSPT result is also positive, evaluate with ultrasound, serum HCGs, additional 
urine testing, or uterine aspiration.
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Figure 2. Sample Instructions for Patients Receiving No-Test 
Abortion
1. Call your abortion provider if: 
£ You vomit within the first 30 minutes after taking mifepristone. 
£ You have a fever of 100.4°F or higher more than 24 hours after you 
take the misoprostol. 
£ One week   after taking misoprostol, you have any of the following:
o You have not had cramping and bleeding heavier than a period. 
o Your bleeding is not getting lighter.
o You do not feel that you passed the pregnancy.
o Your pregnancy symptoms (such as nausea and breast 
tenderness) are not resolving.
£ At any time  , you have any of the following:
o An increase in pain/cramps or bleeding more than 24 hours after 
taking misoprostol.
o Severe pain or cramps that don't get better with pain medicine, 
rest, or heating pads. 
o Enough bleeding to soak 2 maxi pads an hour for more than 2 
hours. 
o Dizziness or vomiting lasting more than 2 hours.
o Weakness, nausea, or diarrhea lasting more than 24 hours. 
2. Perform one urine pregnancy test 4 weeks after taking misoprostol (not 
earlier). Call your abortion provider if the result is positive or 
invalid. Use the second test if instructed to do so by your abortion 
provider.
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